Zealand Pharma Net Income 2017-2021 | ZLDPF

Zealand Pharma net income from 2017 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Zealand Pharma Annual Net Income
(Millions of US $)
2020 $-130
2019 $-86
2018 $92
2017 $-41
2016 $-23
Zealand Pharma Quarterly Net Income
(Millions of US $)
2021-03-31 $-39
2020-12-31 $-59
2020-09-30 $-36
2020-06-30 $-9
2020-03-31 $-27
2019-12-31 $-29
2019-09-30 $-17
2019-06-30 $-21
2019-03-31 $-19
2018-12-31 $-17
2018-09-30 $144
2018-06-30 $-20
2018-03-31 $-15
2017-12-31 $-17
2017-09-30 $-7
2017-06-30 $-14
2017-03-31 $-4
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.133B $0.054B
Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company's pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76